ScoreWhy is Ionis Pharmaceuticals, Inc. ?
1
Poor Management Efficiency with a low ROE of 0.04%
- The company has been able to generate a Return on Equity (avg) of 0.04% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Operating profit has grown by an annual rate -220.04% of over the last 5 years
3
Flat results in Sep 25
- NET SALES(Q) At USD 156.72 MM has Fallen at -33.63%
- DEBT-EQUITY RATIO (HY) Highest at -31.52 %
- OPERATING PROFIT(Q) Lowest at USD -155.68 MM
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 122.89%, its profits have risen by 32.6%
5
Rising Promoter Confidence
- Promoters have increased their stake in the company by 1.19% over the previous quarter and currently hold 2.99% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
6
Market Beating Performance
- The stock has generated a return of 122.89% in the last 1 year, much higher than market (S&P 500) returns of 17.78%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Ionis Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Ionis Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Ionis Pharmaceuticals, Inc.
134.82%
1.75
51.10%
S&P 500
17.78%
0.92
19.35%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
0.73%
EBIT Growth (5y)
-220.04%
EBIT to Interest (avg)
-6.98
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
0.34
Tax Ratio
1.39%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0.04%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
18.56
EV to EBIT
-42.31
EV to EBITDA
-46.05
EV to Capital Employed
75.36
EV to Sales
11.90
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-178.14%
ROE (Latest)
-38.89%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend19What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -247.02 MM
NET SALES(HY)
At USD 608.77 MM has Grown at 69.54%
NET PROFIT(HY)
Higher at USD -16.65 MM
ROCE(HY)
Highest at -39.99%
RAW MATERIAL COST(Y)
Fallen by -1.68% (YoY
-14What is not working for the Company
NET SALES(Q)
At USD 156.72 MM has Fallen at -33.63%
DEBT-EQUITY RATIO
(HY)
Highest at -31.52 %
OPERATING PROFIT(Q)
Lowest at USD -155.68 MM
PRE-TAX PROFIT(Q)
Lowest at USD -158.3 MM
NET PROFIT(Q)
Lowest at USD -158.51 MM
Here's what is working for Ionis Pharmaceuticals, Inc.
Operating Cash Flow
Highest at USD -247.02 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Raw Material Cost
Fallen by -1.68% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Ionis Pharmaceuticals, Inc.
Net Sales
At USD 156.72 MM has Fallen at -33.63%
over average net sales of the previous four periods of USD 236.12 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Pre-Tax Profit
At USD -158.3 MM has Fallen at -151.05%
over average net sales of the previous four periods of USD -63.06 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -158.51 MM has Fallen at -158.06%
over average net sales of the previous four periods of USD -61.43 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Debt-Equity Ratio
Highest at -31.52 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Operating Profit
Lowest at USD -155.68 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
Pre-Tax Profit
Lowest at USD -158.3 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -158.51 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
